RSAD2 Is an Effective Target for High-Yield Vaccine Production in MDCK Cells

Viruses. 2022 Nov 21;14(11):2587. doi: 10.3390/v14112587.

Abstract

Increasingly, attention has focused on improving vaccine production in cells using gene editing technology to specifically modify key virus regulation-related genes to promote virus replication. In this study, we used DIA proteomics analysis technology to compare protein expression differences between two groups of MDCK cells: uninfected and influenza A virus (IAV) H1N1-infected cells 16 h post infection (MOI = 0.01). Initially, 266 differentially expressed proteins were detected after infection, 157 of which were upregulated and 109 were downregulated. We screened these proteins to 23 genes related to antiviral innate immunity regulation based on functional annotation database analysis and verified the mRNA expression of these genes using qPCR. Combining our results with published literature, we focused on the proteins RSAD2, KCNN4, IDO1, and ISG20; we verified their expression using western blot, which was consistent with our proteomics results. Finally, we knocked down RSAD2 using lentiviral shRNA expression vectors and found that RSAD2 inhibition significantly increased IAV NP gene expression, effectively promoting influenza virus replication with no significant effect on cell proliferation. These results indicate that RSAD2 is potentially an effective target for establishing high-yield vaccine MDCK cell lines and will help to fully understand the interaction mechanism between host cells and influenza viruses.

Keywords: DIA; MDCK; RSAD2; influenza virus; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dogs
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza A virus* / physiology
  • Influenza Vaccines* / genetics
  • Influenza, Human*
  • Madin Darby Canine Kidney Cells

Substances

  • Influenza Vaccines

Grants and funding

This research was funded by the National Natural Science Foundation of China (32160164), the scientific research innovation project of Northwest Minzu University (Yxm2021079).